Roles of mitogen-activated protein kinase and phosphoinositide 3′-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling

Experimental Cell Research

Volumn 284, Issue 2, 2003, Pages 289-300

  Vijapurkar, Ulka ^a   Kim, Myong Soo ^a,b   Koland, John G ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Chosun University   (South Korea)

Author keywords

ErbB; HER; Heregulin; MAPK; Phosphoinositide 3 kinase

Indexed keywords

COMPLEMENTARY DNA; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SHC; RECEPTOR SUBTYPE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; ATTENUATION; BINDING SITE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 0037376578     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(02)00040-X     Document Type: Article

References (79)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2:2001;127-137.
2. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network Receptor heterodimerization in development and cancer . EMBO J. 19:2000;3159-3167.
3. Lemke G. Neuregulins in development. Mol. Cell. Neurosci. 7:1996;247-262.
4. Riese D.J. 2nd, Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 20:1998;41-48.
5. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B.J., Sela M., Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15:1996;2452-2467.
6. erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA. 91:1994;8132-8136.
7. Sierke S.L., Cheng K., Kim H.-H., Koland J.G. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 322:1997;757-763.
8. Kim H.-H., Sierke S.L., Koland J.G. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J. Biol. Chem. 269:1994;24747-24755.
9. Soltoff S.P., Carraway K.L. III, Prigent S.A., Gullick W.G., Cantley L.C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14:1994;3550-3558.
10. Wallasch C., Weiss F.U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14:1995;4267-4275.
11. Olayioye M.A., Graus-Porta D., Beerli R.R., Rohrer J., Gay B., Hynes N.E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 18:1998;5042-5051.
12. Sundaresan S., Roberts P.E., King K.L., Sliwkowski M.X., Mather J.P. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology. 139:1998;4756-4764.
13. Sliwkowski M.X., Schaefer G., Akita R.W., Lofgren J.A., Fitzpatrick V.D., Nuijens A., Fendly B.M., Cerione R.A., Vandlen R.L., Carraway K.L. III. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269:1994;14661-14665.
14. Pinkas-Kramarski R., Shelly M., Glathe S., Ratzkin B.J., Yarden Y. Neu differentiation factor neuregulin isoforms activate distinct receptor combinations. J. Biol. Chem. 271:1996;19029-19032.
15. Carraway K.L. III, Soltoff S.P., Diamonti A.J., Cantley L.C. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270:1995;7111-7116.
16. Cohen B.D., Kiener P.A., Green J.M., Foy L., Fell H.P., Zhang K. The relationship between human epidermal growth factor-like receptor expression and cellular transformation in NIH 3T3 cells. J. Biol. Chem. 271:1996;30897-30903.
17. Zhang K., Sun J.L., Liu N.L., Wen D.Z., Chang D., Thomason A., Yoshinaga S.K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271:1996;3884-3890.
18. Alimandi M., Romano A., Curia M.C., Muraro R., Fedi P., Aaronson S.A., Di F.P., Kraus M.H. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 10:1995;1813-1821.
19. Siegel P.M., Ryan E.D., Cardiff R.D., Muller W.J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice implications for human breast cancer . EMBO J. 18:1999;2149-2164.
20. Kraus M.H., Popescu N.C., Amsbaugh S.C., King C.R. Overexpression of the EGF receptor-related proto-oncogene ErbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6:1987;605-610.
21. Peles E., Ben-Levy R., Tzahar E., Liu N., Wen D., Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12:1993;961-971.
22. Kraus M.H., Fedi P., Starks V., Muraro R., Aaronson S.A. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc. Natl. Acad. Sci. USA. 90:1993;2900-2904.
23. Maurer C.A., Friess H., Kretschmann B., Zimmermann A., Stauffer A., Baer H.U., Korc M., Buchler M.W. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum. Pathol. 29:1998;771-777.
24. Hellyer N.J., Cheng K., Koland J.G. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 333:1998;757-763.
25. Vijapurkar U., Cheng K., Koland J.G. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase. J. Biol. Chem. 273:1998;20996-21002.
26. Batzer A.G., Rotin D., Ureña J.M., Skolnik E.Y., Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 14:1994;5192-5201.
27. Okabayashi Y., Kido Y., Okutani T., Sugimoto Y., Sakaguchi K., Kasuga M. Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. J. Biol. Chem. 269:1994;18674-18678.
28. Ricketts W.A., Rose D.W., Shoelson S., Olefsky J.M. Functional roles of the Shc phosphotyrosine binding and Src homology 2 domains in insulin and epidermal growth factor signaling. J. Biol. Chem. 271:1996;26165-26169.
29. Dankort D.L., Wang Z., Blackmore V., Moran M.F., Muller W.J. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol. Cell. Biol. 17:1997;5410-5425.
30. Kavanaugh W.M., Turck C.W., Williams L.T. PTB domain binding to signaling proteins through a sequence motif containing phosphotyrosine. Science. 268:1995;1177-1179.
31. Ricci A., Lanfrancone L., Chiari R., Belardo G., Pertica C., Natali P.G., Pelicci P.G., Segatto O. Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene. 11:1995;1519-1529.
32. Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J. Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol. Cell. Biol. 15:1995;2500-2508.
33. Guan K.L. The mitogen activated protein kinase signal transduction pathway from the cell surface to the nucleus . Cell. Signall. 6:1994;581-589.
34. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. 9:1995;726-735.
35. Robbins D.J., Zhen E., Cheng M., Xu S., Ebert D., Cobb M.H. MAP kinases ERK1 and ERK2 pleiotropic enzymes in a ubiquitous signaling network . Adv. Cancer Res. 63:1994;93-116.
36. Posada J., Cooper J.A. Requirements for phosphorylation of MAP kinase during meiosis in Xenopus oocytes. Science. 255:1992;212-215.
37. Pages G., Lenormand P., L'Allemain G., Chambard J.-C., Meloche S., Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. J. Biol. Chem. 90:1993;8319-8323.
38. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:1994;2831-2841.
39. Hellyer N.J., Kim M.-S., Koland J.G. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 coreceptor. J. Biol. Chem. 276:2001;42153-42161.
40. Varticovski L., Harrison F.D., Keeler M.L., Susa M. Role of PI 3-kinase in mitogenesis. Biochim. Biophys. Acta. 1226:1994;1-11.
41. Toker A., Cantley L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature. 387:1997;673-676.
42. Lin J., Adam R.M., Santiestevan E., Freeman M.R. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59:1999;2891-2897.
43. Dahl J., Freund R., Blenis J., Benjamin T.L. Studies of partially transforming polyomavirus mutants establish a role for phosphatidylinositol 3-kinase in activation of pp70 S6 kinase. Mol. Cell. Biol. 16:1996;2728-2735.
44. Klippel A., Kavanaugh W.M., Pot D., Williams L.T. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol. Cell. Biol. 17:1997;338-344.
45. Kulik G., Klippel A., Weber M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17:1997;1595-1606.
46. Kennedy S.G., Wagner A.J., Conzen S.D., Jordan J., Bellacosa A., Tsichlis P.N., Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptic signal. Genes Dev. 11:1997;701-713.
47. Aoki M., Batista O., Bellacosa A., Tsichlis P., Vogt P.K. The akt kinase Molecular determinants of oncogenicity . Proc. Natl. Acad. Sci. USA. 95:1998;14950-14955.
48. Park B.-K., Zeng X., Glazer R.I. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res. 61:2001;7647-7653.
49. Adam L., Vadlamudi R., Kondapaka S.B., Chernoff J., Mendelsohn J., Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 273:1998;28238-28246.
50. Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., Wallasch C., Daly R.J. Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J. Biol. Chem. 273:1998;7717-7724.
51. Yoo J.Y., Hamburger A.W. Interaction of the p23/p198 protein with ErbB-3. Gene. 229:1999;215-221.
52. Luttrell D.K., Lee A., Lansing T.J., Crosby R.M., Jung K.D., Willard D., Luther M., Rodriguez M., Berman J., Gilmer T.M. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA. 91:1994;83-87.
53. Muthuswamy S.K., Muller W.J. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene. 11:1995;271-279.
54. Karni R., Jove R., Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 18:1999;4654-4662.
55. Hellyer N.J., Kim H.-H., Greaves C.H., Sierke S.L., Koland J.G. Cloning of the rat ErbB3 cDNA and characterization of the recombinant protein. Gene. 165:1995;279-284.
56. White M.F., Backer J.M. Preparation and use of anti-phosphotyrosine antibodies to study structure and function of insulin receptor. Methods Enzymol. 201:1991;65-79.
57. Kim H.H., Vijapurkar U., Hellyer N.J., Bravo D., Koland J.G. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem. J. 334:1998;189-195.
58. Baldin V., Lukas J., Marcote M.J., Pagano M., Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:1993;812-821.
59. Quelle D.E., Ashmun R.A., Shurtleff S.A., Kato J.Y., Bar-Sagi D., Roussel M.F., Sherr C.J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7:1993;1559-1571.
60. Lee R.J., Albanese C., Fu M., D'Amico M., Lin B., Watanabe G., Haines G.K. 3rd, Siegel P.M., Hung M.C., Yarden Y., Horowitz J.M., Muller W.J., Pestell R.G. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20:2000;672-683.
61. Wennstrom S., Downward J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell. Biol. 19:1999;4279-4288.
62. El Urich M., Shemerly M., Besser D., Nagamine Y., Ballmer-Hofer K. Activation and nuclear translocation of mitogen-activated protein kinases by polyomavirus middle-T or serum depend on phosphatidylinositol 3-kinase. J. Biol. Chem. 270:1995;29286-29292.
63. Hu Q., Klippel A., Muslin A.J., Fantl W.J., Williams L.T. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science. 268:1995;100-102.
64. Duckworth B.C., Cantley L.C. Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin - Dependence of signal strength. J. Biol. Chem. 272:1997;27665-27670.
65. Ferby I.M., Waga I., Sakanaka C., Kume K., Shimizu T. Wortmannin inhibits mitogen-activated protein kinase activation induced by platelet-activating factor in gulnea pig neutrophils. J. Biol. Chem. 269:1994;30485-30488.
66. Chang H.W., Aoki M., Fruman D., Auger K.R., Bellacosa A., Tsichlis P.N., Cantley L.C., Roberts T.M., Vogt P.M. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science. 276:1997;1848-1850.
67. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science. 286:1999;1741-1744.
68. erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell. Growth Differ. 7:1996;551-561.
69. Porras A., Alvarez A.M., Valladares A., Benito M. p42/p44 mitogen-activated protein kinases activation is required for the insulin-like growth factor-I/Insulin induced proliferation, but inhibits differentiation, in rat fetal brown adipocytes. Mol. Endocrinol. 12:1998;825-834.
70. Klippel A., Escobedo M.A., Wachowicz M.S., Apell G., Brown T.W., Giedlin M.A., Kavanaugh W.M., Williams L.T. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell. Biol. 18:1998;5699-5711.
71. Frevert E.U., Kahn B.B. Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity, and DNA synthesis in 3T3-L1 adipocytes. Mol. Cell. Biol. 17:1997;190-198.
72. Daly J.M., Olayioye M.A., Wong A.M., Neve R., Lane H.A., Maurer F.G., Hynes N.E. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells Role of P13 kinase and p38 MAP kinase pathways . Oncogene. 18:1999;3440-3451.
73. Beslu N., LaRose J., Casteran N., Birnbaum D., Lecoq E., Dubreuil P., Rottapel R. Phosphatidylinositol-3′ kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase. J. Biol. Chem. 271:1996;20075-20081.
74. Cheng M., Sexl V., Sherr C.J., Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. USA. 95:1998;1091-1096.
75. Lavoie J.N., L'Allemain G., Brunet A., Muller R., Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271:1996;20608-20616.
76. Gille H., Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J. Biol. Chem. 274:1999;22033-22040.
77. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:1998;3499-3511.
78. Webster M.A., Hutchinson J.N., Rauh M.J., Muthuswamy S.K., Anton M., Tortorice C.G., Cardiff R.D., Graham F.L., Hassell J.A., Muller W.J. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell. Biol. 18:1998;2344-2359.
79. Markland W., Smith A.E. Mutants of polyomavirus middle-T antigen. Biochem. Biophys. Acta. 907:1987;299-321.